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Major new health issues confront us; some 
of which arise from our modern lifestyle and 
its consequent energy imbalance. In addi-
tion to obesity and diabetes, metabolic dis-
turbances will soon overtake smoking as the 
main avoidable cause of cancer. Reductions 
in infectious diseases and infant mortality 
together with people living longer result in 
population growth and an increased need 
for effective population control: a clear chal-
lenge for reproductive endocrinology. Many 
more people living to old age increases the 
prevalence of all conditions associated with 
aging. Until recently aging was generally 
considered to be due to wear-and-tear and 
cumulative tissue damage. Studies from 
experimental genetics have however now 
clearly demonstrated that aging is regulated 
by hormonal pathways and that longevity 
can be dramatically extended; raising the 
potential for endocrine-based interven-
tions for many age-related conditions. 
Assessing and treating endocrine disorders 
in the very elderly or considering endocrine 
interventions to counter frailty is however 
challenging because of limited normative 
data and a lack of understanding of normal 
endocrinology in this age group. A further 
challenge will be to balance quantity-of-life 
with quality-of-life.
Rodent models have been widely used 
in endocrinology but there are concerns 
regarding their use as models of these new 
human conditions that are a consequence 
of metabolic disorders related to gene– 
environment interactions. Laboratories use 
genetically homogeneous rodent colonies 
and hence examine the effect of exposures 
on a single genotype. Human populations 
however comprise infinitely varied geno-
types which can respond in many differ-
ent ways to the same exposures; even in the 
most obesogenic environment only some 
individuals become obese. In addition the 
standard rodent experiment compares an 
intervention group to an untreated control 
group. These control animals however live a 
sedentary life with continuous access to food, 
within confined containers in  standardized 
conditions with constant day–night cycles 
and hence no environmental stimuli. As a 
result these “control” animals are relatively 
overweight, insulin resistant and live much 
shorter lives than “normal” rodents liv-
ing in their natural habitats that exercise 
considerably more and feed intermittently 
(Martin et al., 2010). Interventions that are 
perceived to induce metabolic advantage in 
such experiments are in many cases just cor-
recting these abnormalities present in the 
control animals. This experimental para-
digm may have had many unwitting con-
sequences; for example many new cancer 
therapies exhibit efficacy in animal studies 
but then prove to be ineffective in human 
clinical trials. Is this because tumor devel-
opment is different in the metabolically 
moribund animals used in the preclinical 
trials? Similarly most cell culture experi-
ments are traditionally performed in very 
hyperglycemic media which can alter many 
cell responses. A challenge will be to develop 
more appropriate experimental models.
Historically endocrinology studied a 
few discrete endocrine glands but it is now 
clear that most tissues release soluble sig-
nals. Adipose tissue, once regarded as just 
a passive energy store, is now recognized 
as a dynamic source of hormones such as 
leptin and adiponectin. The gastrointesti-
nal tract secretes ghrelin and incretins and 
muscle is a source of myokines. With ever 
growing complexities each of the endocrine 
systems has become a field within itself, 
being an expert in thyroid endocrinology 
for example, involves integrating consider-
able information from structural chem-
istry through to clinical management. 
Integrating all of this information for more 
than one system is challenging. In the body, 
cells never see any hormone in isolation; 
they are exposed to many varying signals. 
Experiments usually test how one variable 
affects one response, examining a dynamic 
response adds a third-dimension: concep-
tualizing in more than 3D has constrained 
more  complex  experiments. To move the 
experimental paradigm closer to reality will 
require the use of techniques such as math-
ematical modeling and network analysis.
Technical advances are now occurring 
so rapidly that interpretation struggles to 
keep apace. It is now possible to examine 
virtually all of the genetic variants across 
the entire genome and their association 
with endocrine disorders such as obesity 
and diabetes. Early genome-wide associa-
tion studies indicate that large numbers of 
genes generally each contribute small effects 
to these common conditions and most 
are dependent upon gene–environment 
interactions. The first robust association 
with obesity was the fat mass and obesity-
associated gene, FTO (Frayling et al., 2007). 
More recently it was reported that this asso-
ciation was not present in an older popula-
tion not exposed to the current obesogenic 
environment (Jacobsson et al., 2009) and 
the association could also be overcome in 
young people who meet recommended 
levels of daily physical activity (Ruiz et al., 
2010); implying that FTO was not causal 
but was a susceptibility gene affecting the 
response to energy imbalance. Changes in 
all of the genes that respond to a hormone 
can now be arrayed and this can even be 
examined dynamically using gene expres-
sion dynamic imaging. Further complex-
ity has emerged from epigenetics: many 
genes can be reprogrammed by a variety of 
mechanisms enabling adaptation to altered 
circumstances such as changing availability 
of food and water. As these functions are 
hormonally controlled it is not surprising 
that these controls can be epigenetically 
reprogrammed. Such programming con-
tinues from in utero at least throughout 
childhood. Pediatric endocrinologists need 
to understand these adaptations and their 
long-term consequences. Childhood obes-
ity indicates disturbed metabolism at an age 
when there is still plasticity and the poten-
tial for reprogramming endocrine systems. 
This may lead to long-term  consequences 
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imaging is evolving with new probes: for 
example imaging for hyperparathyroidism 
is now possible with either dual-isotope 
subtraction imaging or single-isotope 
dual-phase imaging and the distinction of 
parathyroid and thyroid glands provided by 
SPECT can be combined with anatomical 
information provided by CT (Eslamy and 
Ziessman, 2008). The application of nano-
particles and Qdots will confer immunohis-
tochemical specificity to clinical imaging; 
already used for experimental animals and 
will be translated to the clinic as soon as tox-
icology issues have been solved (Bentolila 
et al., 2009). This will enable hormones, 
drugs, antibodies, and cells to be tagged 
with nanoparticles and tracked within 
the body; such as herceptin-targeted MRI 
imaging of breast cancer cells (Huh et al., 
2005) and VEGF-conjugated Qdots for 
PET imaging of angiogenesis (Chen et al., 
2008). Multifunctional nanoparticles will 
enable multifunctional imaging and other 
developments such as metallic nanoparti-
cles with photothermal properties for com-
bined targeted imaging and laser ablation 
therapy. Nanostructures mimicking biolog-
ical systems are being developed including 
motorized nanoparticles and more com-
plex structures with DNA (Gu et al., 2010) 
or RNA (Guo, 2005) based assembly. Such 
complex nanostructures could eventually 
carry antibodies linked to Qdots or para-
magnetic particles for target imaging and 
subunits that induce receptor-mediated 
endocytosis, disruption of endosomes and 
release of drugs, and a final subunit with 
a further label for imaging of the planned 
outcome such as apoptosis.
Endocrinology is now central to the 
major current health issues of aging, 
population control, and the pandemics 
of obesity, diabetes, and cancer. I have 
described some examples of exciting new 
technologies: applying these and mak-
ing sense of the mountains of new data 
that they will generate and translating 
all of this into new understanding and 
benefits for patients is the challenge for 
endocrinology.
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in addition to all of the  recognized sequalae 
of obesity that normally develops in mid-
life. In addition to genetics and epigenetics, 
there have been important developments 
in RNA-biology with the discovery of 
microRNA and multiple RNA binding 
proteins and splicing factors. Advances 
in proteomics and metabolomics are also 
yielding unprecedented volumes of infor-
mation regarding hormone processing and 
 hormonal effects.
Advances in chemistry and physics have 
opened exciting new windows to the worlds 
of cellular and molecular endocrinology. We 
can now actually see the subtle twists and 
turns that occur when a hormone engages 
with its receptor and study these events 
with techniques such as single-molecule 
fluorescence microscopy, FRET, FRAP, and 
FLIM (fluorescence energy transfer, fluo-
rescence recovery after photobleaching, and 
fluorescence lifetime imaging microscopy). 
Quantum dots (Qdots) are extremely bright 
and photostable nano-sized crystalline clus-
ters making them useful probes for fluores-
cence imaging, facilitating multiplexing, and 
with particular advantages for FRET and 
two-photon excitation microscopy (Pinaud 
et al., 2010). Atomic Force Microscopy can 
be used in combination with techniques 
such as scanning fluorescence correlation 
spectroscopy and fluorescence lifetime 
correlation spectroscopy to study ligand/
receptor interactions on live cells (Chen 
and Irudayaraj, 2010). Labeled nanoparti-
cles can be manipulated with optical tweez-
ers for 3D nanoscale imaging which with 
video-goggles enable the viewer to move 
around cells or molecular structures in the 
virtual nanoworld. Touch-pads can be used 
to manipulate ligands onto receptors and 
then gently tug to assess binding forces. 
When linked to tactile-gloves this even 
enables the investigator to feel the surface 
of cells or large molecular structures. A chal-
lenge will be to translate this new molecular 
insight into information that may benefit 
patients, such as better design of molecular 
mimetics and antagonists.
There have been similar advances in 
clinical imaging techniques including 
ultrasound, scintigraphy, angiography, 
computed tomography (CT) including 
single-photon emission CT (SPECT), MRI, 
and PET; aiding patient evaluation, diag-
nosis, and monitoring response. Functional 
